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Neuronostatin (NST) is a peptide encoded by the somatostatin
gene that serves important physiological functions in diverse
tissues. Previous studies have shown that intracerebroventricular
administration of NST induces antinociceptive effects and
hyperalgesic effects as determined by the tail immersion assay and
formalin test, respectively. In the present study, we aimed to
evaluate the effects of intrathecal (i.t.) injection of NST on
nociception in a model of visceral pain, and determine possible
mechanisms of action in mice. NST (1, 3, 6, or 12 nmol) was
administered to mice, leading to a dose‐dependent antinociceptive
effect as determined by the acetic acid‐induced writhing test in
mice. NST (1 nmol) also enhanced the antinociceptive effect of
morphine (2.5 and 5 μg/kg) in the spine. Naloxone and
β‐funaltrexamine hydrochloride significantly antagonized the
antinociceptive effect of NST. The expression of G‐protein‐coupled
receptor 107 (GPR107) protein and the phosphorylation of PKA at
Thr197 were increased after i.t. administration of NST, suggesting
that the μ‐opioid receptor and GPR107/PKA signaling pathway are
involved in the analgesic response. In conclusion, i.t. injection of
NST may potentially be used as a new approach in the mediation
of visceral pain.
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1

Introduction

Somatostatin is a peptide secreted by neuro‐
endocrine cells in the gastrointestinal and
central nervous system (CNS), and regulates
diverse actions by binding to the five different
isoforms of the somatostatin receptor [1, 2].

Neuronostatin (NST), also encoded by the
somatostatin gene, plays important physiological
roles in diverse tissues. It not only inhibits
growth hormone and luteinizing hormone
secretion in baboon (Papio anubis) primary
pituitary cell cultures, but also suppresses food
and water intake [3, 4]. In the CNS, NST is primarily
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expressed in the cortex and hypothalamic
paraventricular nucleus, though it also induces
c‐fos expression in the cerebellum and hip‐
pocampus [4, 5]. NST elevates intracellular Ca2+
concentration
in
hypothalamic
neurons,
significantly impairs memory retention, and
induces depression‐like effects [5–8]. Some of
the effects of NST are mediated through
G‐protein‐coupled receptor 107 (GPR107), as
intracerebroventricular (i.c.v.) administration of
GPR107 siRNA blocks the effect of NST in the
elevation of mean arterial pressure [9]. Therefore,
GPR107 represents a promising candidate
receptor for NST.
The sensing of pain is complex, and mediated
by many components. Nociceptors express
transient receptor potentials at the nerve
terminals, and sensory afferents transmit this
signal to spinal nociceptive neurons, located in
the dorsal horn of the spinal cord. This is
followed by supraspinal integration and
descending regulation of pain perception [10,
11]. The spinal and supraspinal injections of
drugs may exert different effects; for example,
intrathecal (i.t.) or i.c.v. administration of
somatostatin produces analgesic effects as
measured by the tail immersion acute test, and
in chronic inflammatory pain [12]. I.c.v. injection
of angiotensin II has no effect on the nociceptive
response in the tail‐pinch test, but i.t. injection of
angiotensin II leads to an antinociceptive effect
in the tail immersion test [13, 14]. Therefore, it is
possible that NST can regulate pain sensing at
the spinal level.
Visceral pain is a complex disorder and
difficult to manage effectively, as its signals and
neurobiological mechanisms differ from the
characteristics of somatic sensation [15, 16]. It
has been reported that visceral noxious
information could be transmitted through
different neural pathways at spinal sites [15].
Intestinal afferent nerves convey sensory
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information of visceral pain to the CNS, and it is
known that spinal activity plays an important
role in the process [17]. Previous studies have
shown that i.c.v. administration of NST induces
antinociceptive effects as determined by the tail
immersion test, as well as significantly enhances
the antinociceptive effect of morphine in mice
[18, 19]. In addition, NST can reduce the
inflammatory infiltration of acute pancreatitis in
rats [20]. However, the effects of NST in visceral
pain have not yet been reported at the spinal
level.
The present study focused on evaluating the
effect of i.t. injection of NST on visceral
nociception in the acetic acid‐induced writhing
test in mice. Receptor antagonists and protein
expression were analyzed to determine potential
signaling mechanisms of NST.

2

Material and methods

2.1 Experimental animals
A total of 386 four‐month‐old male Kunming
strain Swiss mice weighing between 18–22 g
were utilized for this study. Mice were obtained
from Lanzhou University Animal Center
(China), housed in pathogen‐free facilities (5–6
mice per cage), and maintained in 12:12 h
light/dark cycle conditions (lights on from 7: 00
a.m. to 7: 00 p.m.) at 22 ± 2 ℃ in a pathogen‐
free room. The animals were given access to
food and water ad libitum, and were allowed to
become accustomed to the laboratory environ‐
ment for one week prior to the initiation of
experiments.
Mice were randomly divided into two major
groups, the behavioral test (n = 350) and
Western blot (n = 36) groups. The behavioral
test group (Group 1) was divided into
subgroups were as follows: n = 12 for pain tests
in every group; n = 11 for antagonist and
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(1:1000; Catalog number 4782); phospho‐PKAc
Thr197 (1:1000; Catalog number 4781); and
phospho‐Akt Ser473 (1:1000; Catalog number
9271). The GPR107 (1:1000; Catalog number
25076‐1‐AP) and Akt (1:1000; Catalog number
10176‐2‐AP) were obtained from Proteintech Co.
(Hebei, China). GAPDH (Catalog number
K106389P) was provided by Solarbio Co. (Beijing,
China). Appropriate secondary antibodies were
obtained from Solarbio Co. (Beijing, China).

GPR107 siRNA experiments; n = 10 for
locomotor activity assays; n = 12 for morphine
experiments; and n = 14 for naloxone tests,
respectively. The Western blot group (Group 2)
was divided into subgroups as follows: n = 6 in
each experimental group.
All of the experimental manipulations were
completed following the guideline recommend‐
ations for the care and use of experimental
animals provided by Northwest Normal
University Ethical Committee for Human and
Animal Experimentation, as well as the
guidelines from the China Council on Animal
Care and the Guide for the Care and Use of
Laboratory Animals (1996, published by National
Academy Press, 2101 Constitution Ave. NW,
Washington, DC 20055, USA). All pain testing
procedures were performed by an observer
double‐blinded to the study.
All the experiments were conducted in
compliance with the ARRIVE guidelines.

into the subarachnoid space. Then, 5 μL of either

2.2 Drugs and antibodies

drug or vehicle was administered intrathecally

2.3 Intrathecal injection
Intrathecal (i.t.) administration was performed
manually as previously described [21]. The
unanesthetized mice were held by a pelvic
girdle after sterilization, and a 27‐gauge needle
attached to a 25 μL Hamilton micro‐syringe was
inserted between the L5 and L6 lumbar
vertebrae. A sudden tail slight flick or “S” curl
was used as the indicator for appropriate insertion

at a speed of 5 μL/10 s according to different
Neuronostatin (Leu‐Arg‐Gln‐Phe‐Leu‐Gln‐Lys‐
Ser‐Leu‐Ala‐Ala‐Ala‐Ala‐NH2) used in this
study was purchased from Hangzhou Chinese
Peptide Biochemical Co. (Jiangsu, China), and
was dissolved in artificial cerebrospinal fluid
(CSF; 126.6 mM NaCl, 27.4 mM NaHCO3, 2.4
mM KCl, 0.5 mM KH2PO4, 0.89 mM CaCl2, 0.8
mM MgCl2, 0.48 mM Na2HPO4, and 7.1 mM
glucose, pH 7.4). The naloxone hydrochloride
dehydrates, β‐funaltrexamine hydrochloride
(β‐FNA) and bicuculline methiodide, were
purchased from Sigma (MO, USA). Morphine
hydrochloride was acquired from Shenyang
First Pharmaceutical Factory (Liaoning, China).
These were dissolved in dimethyl sulfoxide
(DMSO) and diluted in artificial CSF. The final
concentration of DMSO was less than 0.1%. The
following antibodies were purchased from Cell
Signaling Technology Co. (MA, USA): PKAc

experiment time. GPR107 siRNA (100 nmol; 5’
‐GAUCGGAGUAAGAACGAUGGCUTT‐3’) was
injected into the spinal cord (2 μL in total) at the
same location. After two days, spinal cord
tissues were collected for Western blot analysis.
Intrathecal

co‐injection

was

performed

as

previously described [22], and the antagonists
were administered i.t. 10 min prior to injection
of NST with different syringes. Morphine was
co‐injected i.t. with NST in accordance with the
method described previously [18]. Following
completion of the behavioral experiments, the
placement of cannula was verified by administra‐
tion and localization of a 1% methylene blue
dye, which diffused into the proximal and
distal regions of the spinal cords, but was not
found in the brain tissue following anatomical
dissection.

https://mc03.manuscriptcentral.com/brainsa

| Brain Science Advances

347

Brain Sci. Adv.

2.4 Acetic acid‐induced writhing test
Chemical‐induced visceral pain was evaluated
using the acetic acid‐induced writhing test as
described previously [22]. Drugs or vehicle CSF
were administered 5 min prior to the
administration of acetic acid. A 1% acetic acid
solution (10 mL/kg) was intraperitoneally (i.p.)
injected according to the method used in a
previous study [23]. The mice were placed in
individual cages for observation. The number of
writhes or abdominal constrictions, such as
elongation of the body and extension of the
forelimb, development of tension in the
abdominal muscles, and arching of the back,
were considered visceral pain reactions. These
behaviors were recorded during a 30‐minute
period. In order to avoid unnecessary pain to
the experimental animals, the durations of
experiments were as short as possible, and the
mice were immediately anesthetized following
the treatment period.
2.5 Locomotor activity test
The spontaneous locomotor activity of mice was
examined and moderated by a ZZ‐6 Autonomous
Movement Instrument for Mice (Chengdu TME
Technology Co. Ltd., China) in accordance with
the previously described method [8]. This
instrument is comprised of separated rooms; the
mice were habituated in the apparatus for 10
min prior to i.t. administration, and then
immediately placed into their former rooms to
measuring their locomotor activities at 5‐min
intervals for 30 min. The sum of both horizontal
and rearing movements were recorded. After
each test session, the apparatus was cleaned to
minimize influence of any odors, such as the
urine and feces of the previously examined
mouse.
2.6 Western blot analysis
10 min after NST or artificial CSF administration,
mice were anesthetized with sodium pentobarbital

http://bsa.tsinghuajournals.com

(90 mg/kg, i.p.) and the lumbar segment of
spinal cords were quickly removed. The spinal
dorsal horns were dissected from this tissue and
homogenized in a 10‐fold excess volume of ice
cold RIPA protein lysis buffer (Solarbio, Beijing,
China), which contained 1 mM PMSF, 0.1% (v/v)
2‐mercaptoethanol, and a 1:100 dilution of
protease inhibitor cocktail. The homogenates
were left on ice and centrifuged at 14 000g for 15
min at 4 ℃. Supernatants were collected, and
protein concentrations were determined using
the Bradford method [24]. 30 μg of total protein
extracts were boiled for 5 min and separated
using a 7.5% to 10% SDS‐PAGE run in SDS
buffer [25 mM Tris‐HCl, pH 8.5, 192 mM glycine,
0.1% (w/v) SDS] for 60–100 min at 150 V,
depending on the percentage of the gel. The
proteins were transferred to nitrocellulose
membranes (Whatman, Maidstone, UK) using a
wet transfer system in transfer buffer (25 mM
Tris‐HCl, pH 8.5, 192 mM glycine, 20%
methanol) for 90 min at 100 V. The membranes
were incubated with primary antibodies in 0.5%
BSA/1× TBST overnight at 4 ℃ after blocking
with 10% nonfat milk. The specimens were then
immunoblotted with corresponding horseradish
peroxidase‐conjugated secondary antibodies
(1:5 000) for 1.5 h at room temperature. Blots
were visualized using an enhanced chemilumin‐
escence (ECL) reagent, detected using a
ChemiDoc MP Imaging System (Bio‐Rad,
Hercules, California, USA), and quantified using
ImageJ software.
2.7 Experimental design
In order to investigate the effects of NST on
acetic acid‐induced visceral pain in mice, NST
was administered i.t. at a dose of 1, 3, 6, or 12
nmol/mouse, respectively, 5 min prior to acetic
acid injection. Control animals received no NST,
but artificial CSF. In order to evaluate whether
synergistic analgesic effects between NST and
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morphine were present at the spinal level, the
mice were injected with morphine (2.5, 5, or 10
μg/kg) alone or co‐administered (i.t.) with the
minimal analgesic dose of NST (1 nmol/mouse),
respectively. Dosages of NST were based on the
available literature and this study’s preliminary
experimental results [19, 25].
For the purpose of determining pain
mechanisms affected by NST, the γ‐aminobutyric
acid receptor antagonist bicucullin (1.086 nmol/
mouse), classical opioid receptor antagonist
naloxone (10 nmol/mouse), and the μ‐opioid
receptor antagonist β‐FNA (10 nmol/mouse)
were used. The dosages of these antagonists
were chosen in accordance with previous
related studies [18, 19, 25].
To determine the role of GPR107 in the
antinociceptive effect induced by NST, GPR107
siRNA (100 nmol/mouse) was administered i.t.
2 days prior to NST injection. The dosage of
GPR107 siRNA was chosen according to
previous results [8]. To further examine pain
mechanisms, Western blot was used to examine
signaling mediators of the GPR107/PKA/Akt
signaling pathway after i.t. administration of
NST.
2.8 Statistical analysis
All data are represented as means ± standard
error of mean (SEM), and were assessed using
SPSS software version 19.0 (SPSS Inc., Chicago,
IL, USA). The statistical methods were chosen
in accordance with previous related studies [8,
18, 19, 25]. The data obtained from behavioral
and Western blot assays were assessed by
one‐way or two‐way ANOVA followed by
post hoc analysis using Dunnett’s test. The
differences between two groups were
determined using an unpaired, two‐tailed
Student’s t test. P values < 0.05 were considered
statistically significant.

3

Results

3.1 NST produced antinociception in the acetic
acid‐induced visceral pain model and
enhanced analgesia caused by morphine
I.t. administration of NST (1–12 nmol/mouse)
decreased the number of writhes in a dose‐
dependent manner in the acetic acid‐induced
writhing test of visceral pain [Fig. 1(A)]. The
total number of contractions was statistically
reduced at doses of 3, 6, and 12 nmol
NST/mouse when compared with control group
(P < 0.05, P < 0.01, P < 0.05, respectively). The
most effective dose was 6 nmol/mouse. In order
to determine whether this analgesic effect was
dependent on the opioid receptor or GABA
system, naloxone, β‐FNA, or bicuculline was
co‐injected i.t. with NST. Naloxone and β‐FNA
both significantly antagonized the reduction in
the total number of writhes caused by NST (P <
0.01 and P < 0.05, respectively) [Fig. 1(B) and
(C)]. However, naloxone or β‐FNA alone did not
affect the number of writhes. These results
demonstrated that the μ‐opioid receptor was
involved in the antinociceptive effect of NST in
the visceral pain model. However, i.t. injection
of bicuculline alone, or in combination with NST,
did not change the total number of writhes,
suggesting that the GABAA system was not
involved in this process [Fig. 1(D)]. Furthermore,
GPR107 siRNA significantly eliminated the
reduction in the number of writhes when
compared with NST treatment [Fig. 1(E), P <
0.01]. In order to exclude the effect of motor
ability on pain‐related behaviors, the locomotor
activity was determined. The 30‐min spontaneous
locomotor activity counts at 5‐min intervals
were not found to be statistically different
among all treatment groups [Fig. 1(F)],
indicating that the abdominal constrictions were
not caused by locomotor inhibition.
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Effect of i.t. injection of neuronostatin (NST) on nociception in the acetic acid‐induced writhing test. (A) Numbers of writhes in the

acetic acid‐induced writhing test are shown in response to different doses of NST (1, 3, 6, and 12 nmol/mouse). All data are presented as means
± SEM of n = 12 mice per group. * P < 0.05 and ** P < 0.01 when compared with the vehicle group. Number of writhes in the acetic acid‐induced
writing test following i.t. co‐administration of (B) opioid receptor antagonist naloxone (10 nmol/mouse), (C) μ‐opioid receptor antagonist
β‐FNA (10 nmol/mouse), (D) γ‐aminobutyric acid receptor antagonist bicuculline (1.086 nmol/mouse), and (E) GPR107 siRNA (100 nmol) with
NST (6 nmol/mouse), respectively (n = 11 mice per group, ** P < 0.01 when compared with the vehicle group, and ## P < 0.01 when compared
with NST group). (F) Locomotor activity was recorded following NST treatment, in which complete time‐courses at 5‐min intervals for 30 min
were calculated (n = 10 mice per group). (G) Antinociceptive response to morphine following co‐injection (i.t.) of NST (1 nmol/mouse) and
morphine (2.5 and 5 μg/kg) in the acetic acid‐induced writhing test (n = 12 mice per group, $ P < 0.05 and $$ P < 0.01 when compared with the
vehicle group; ** P < 0.01 indicates difference between NST + morphine versus morphine alone; # P < 0.05 ## P < 0.01, and ### P < 0.001 indicate
statistically significant differences between the NST + morphine versus NST). (H) Effect of i.t. administration of naloxone (10 nmol/mouse) on
the synergistic analgesic response of i.t. co‐injection of NST (1 nmol/mouse) and morphine (5 μg/kg) in the writhing test (*** P < 0.001 when
compared with the vehicle group; ### P < 0.001 indicates statistically significant difference between NST + morphine versus NST + morphine +
naloxone, n = 14 mice per group). Data were assessed using one‐way or two‐way ANOVA followed by post hoc analysis using Dunnett’s test.
Difference between two groups was determined by the unpaired, two‐tailed Student’s t test. NST, neuronostatin; β‐FNA, β‐funaltrexamine
hydrochloride; Vehicle refers to artificial CSF; Nal, naloxone; BIC, bicuculline.
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The results of a previous related study
revealed the synergistic analgesic effects of NST
and morphine at the supraspinal level in the tail
immersion test [18]. NST (1 nmol/mouse i.t.)
markedly enhanced the antinociceptive effect of
morphine (2.5 or 5 μg/kg) in the acetic acid‐
induced visceral pain model in conscious mice
compared to morphine alone (P < 0.01) [Fig.
1(G)]. However, it was observed that NST
(1 nmol/mouse) did not improve the antinocicep‐
tive effect induced by the highest dose of
morphine (10 μg/kg). Moreover, the analgesic
effects of i.t. co‐injection of NST (1 nmol/mouse)
and morphine (5 μg/kg) was inhibited
by naloxone, but naloxone (10 nmol/mouse)
alone did not influence the analgesic response
[Fig. 1(H)].
3.2 NST increased GPR107 protein expression
and PKA phosphorylation in the spinal
dorsal horn
In order to identify the pain mechanisms induced

Fig. 2

by i.t. administration of NST in mice, GPR107
expression and PKA phosphorylation in the
spinal cord were analyzed. GPR107 protein
expression levels were significantly increased
following i.t. injection of NST in a dose‐
dependent manner when compared with the
vehicle group (3 nmol NST, P < 0.05; 6 and 12
nmol NST, P < 0.01; Fig. 2). PKA was consistently
phosphorylated at the Thr197 residue, which
increased in the spinal dorsal horn after i.t.
administration of NST in mice when compared
with vehicle‐treated group (6 nmol NST, P < 0.01;
and 12 nmol NST, P < 0.05). However, there was
no difference in the phosphorylation of Akt at
Ser473 between the NST and vehicle‐treated
groups (P > 0.05). I.t. injection of GPR107 siRNA
significantly prevented PKA phosphorylation
and GPR107 expression induced by NST. These
results indicate that the analgesic response
induced by i.t. administration of NST is
mediated via the GPR107/PKA signaling pathway

Effect of i.t. administration of neuronostatin (NST) on the GPR107/PKA/Akt signaling pathway in the spinal dorsal horn. NST was

administered i.t. After 10 min, L4–L5 spinal dorsal horn samples were collected and immunoblotting analysis was performed. Band
densitometry quantification of GPR107 was normalized to GAPDH levels; band densitometry quantification of the ratio between
phosphorylated (phosphorylation of PKA at Thr197 and Akt at Ser473 site) and total protein levels (PKA and Akt) are presented at the right,
or expressed as a percentage of the vehicle (artificial CSF) in lower panels. The data are represented by means ± SEM (n = 6 mice/group); * P
< 0.05 and ** P < 0.01 compared to the control using one‐way ANOVA followed by post hoc analysis using Dunnett’s test.
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in the spinal dorsal horn.

4

Discussion

The present study examined the effects of i.t.
administration of NST on visceral nociception in
mice. The results show that NST has an
antinociceptive effect using the acetic acid‐
induced writhing test, and that the endogenous
opioid system and GPR107/PKA signaling
pathway are involved in this antinociception.
Visceral pain is closely related with visceral
hypersensitivity, due to the sensitization of
afferent nerve pathways. Intestinal afferents
convey sensory information of visceral pain to
the CNS, and the activities of spinal neurons
play an important role in the process [17]. Acetic
acid‐induced visceral pain is a suitable model
for visceral hypersensitivity, as it induces
transient low‐level inflammation [15, 16]. NST
had an antinociceptive effect in the acetic
acid‐induced writhing test at the L4 and L5
dorsal root ganglia, where NST is widely
expressed (data not shown), indicating that
exogenous NST contributes to pain sensing at
the spinal level. However, the visceral region is
also innervated by neurons located in the L6
dorsal root ganglia; NST may regulate visceral
pain sensations located in the L6 dorsal root
ganglia which project to the L4 and L5 spinal
cord segments [26]. It was observed that the
most effective analgesic response in the acetic
acid‐induced visceral pain model was evoked by
the dose of 6 nmol/mouse NST, and there were
no further increases in analgesia caused by
either higher or lower doses of NST. A
bell‐shaped dose response curve was observed
for NST, which was similar to those reported for
other bioactive peptides and for the mean
arterial pressure increase caused by NST [4, 8, 18,
19, 25]. These phenomena suggest that NST has
different physiological activity in different doses,
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and activity may also depend on the number of
receptors present in a specific tissue. However,
this hypothesis requires further confirmation.
It has been well documented that the opioid
system modulates nociception at multiple sites
in the CNS, including the spinal cord, midbrain,
and thalamus [27–29]. Peripheral tissue trauma
elicits an increase in production and release of
the two opioid peptide families, dynorphin and
enkephalin, in the dorsal horn of the spinal cord
[22, 30]. Previous studies have also indicated
that different actions induced by NST are
mediated by opioid receptors [18, 19, 25].
Coincidentally, it was observed that naloxone
significantly attenuated the antinociception
effect in the acetic acid‐induced writhing test,
and the μ‐opioid receptor antagonist β‐FNA
was also able to block the reduction in the
amount of writhing induced by NST, suggesting
that the endogenous opioid system is involved
in modulation of the visceral pain response at
the spinal level. Therefore, the interaction
between NST and endogenous opioid system is
a critical event in the modulation of analgesia.
We found that naloxone could effectively
abolish the enhanced analgesic response of
morphine, suggesting that opioid receptors were
involved in improved analgesia induced by NST.
These results indicated that NST dampened
visceral pain effects on nociception via the
μ‐opioid receptor at the spinal level.
Morphine is a potent analgesic, used in the
long‐term treatment of acute and chronic pain,
that acts via the opioid receptor in the spinal
cord. However, morphine can be highly
addictive, and has displayed negative side
effects when administered repeatedly or used at
high doses [31]. Previous studies have revealed
that NST enhances the antinociceptive effect of
morphine at the supraspinal level [18]. The
present study has indicated that i.t. administra‐
tion of NST could improve the analgesia caused
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by a lower dose of morphine (2.5 or 5 μg/kg).
Therefore, a cascade amplification mechanism
may potentially exist to modulate pain
following co‐administration of NST and
morphine in the CNS. On the other hand, i.t.
co‐injection of a high‐dose of morphine (10
μg/kg) and NST did not improve the
antinociceptive effect of morphine alone. These
findings were confirmed by the saturation
phenomena of classical opioid receptors, since
there were insufficient opioid receptors for the
highest dose of morphine and NST [22].
I.t. administration of NST led to increases in
GPR107 protein expression and phosphorylation
of PKA in the spinal cord. GPR107 is considered
to be a candidate receptor for NST [8, 32],
indicating that GPR107 may be implicated in the
regulation of pain by NST downstream of the
PKA signaling pathway. Furthermore, this study
also revealed that i.t. injection of GPR107 siRNA
not only prevented PKA phosphorylation, but
markedly decreased the analgesic effect induced
by NST. These results indicated that i.t.
administration of NST led to antinociceptive
effect in the visceral nociception through the
GPR107/PKA signaling pathway in addition to
the opioid receptor. NST might also increase the
affinity of morphine for the opioid receptors
through the GPR107/PKA signaling pathway in
the visceral pain response. This hypothesis
requires further confirmation.

5

Conclusions

In conclusion, this study demonstrates that i.t.
administration of NST induces antinociception
in the acetic acid‐induced writhing test. This
effect is mediated by the μ‐opioid receptor and
the GPR107/PKA signaling pathway. This study
also shows that NST significantly enhances the
antinociceptive effect of morphine in the
writhing test, a response that is also mediated

by the opioid system. This indicates that i.t.
injection of NST could potentially be used as a
new approach in mediating visceral pain.
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